Citalopram and Omeprazole Co-Administration
Citalopram can be co-administered with omeprazole, but the citalopram dose must be limited to a maximum of 20 mg/day due to significantly increased QT prolongation risk.
Dose Adjustment Required
The FDA drug label explicitly states that citalopram 20 mg/day is the maximum recommended dose in patients taking concomitant omeprazole or another CYP2C19 inhibitor, because of the risk of QT prolongation 1, 2. This is non-negotiable guidance based on the pharmacokinetic interaction where omeprazole, as a potent CYP2C19 inhibitor, substantially increases citalopram exposure.
Mechanism and Magnitude of Interaction
- Omeprazole inhibits CYP2C19, one of the primary enzymes metabolizing citalopram 1
- This interaction increases citalopram plasma concentrations by 35-94% depending on the specific enantiomer 3, 4
- The (+)-(S)-citalopram enantiomer is preferentially affected, with approximately 120% increase in exposure 4
- Escitalopram (the S-enantiomer) shows even greater increases of 93.9% with omeprazole 3
QT Prolongation Risk Assessment
Baseline Risk Factors
Citalopram carries inherent QT prolongation risk, with the highest risk among SSRIs alongside escitalopram 5, 6. The 2023 Canadian Cardiovascular Society guidelines specifically identify citalopram as having the highest arrhythmogenic risk among SSRIs, while paroxetine and sertraline have negligible risk 5.
Critical risk threshold: QTc > 500 ms or drug-induced increase > 60-70 ms significantly increases torsades de pointes (TdP) risk 5.
Synergistic Risk with Combination
A 2019 population-based cohort study demonstrated that concomitant use of citalopram and omeprazole increased sudden cardiac arrest risk with an adjusted hazard ratio of 2.23 (95% CI 1.79-2.78), compared to 1.32 for citalopram alone 7. This represents a clinically meaningful amplification of cardiac risk.
Cardiac Monitoring Recommendations
Obtain a baseline ECG before initiating this combination if any of the following are present 5:
- Severe electrolyte disturbances (hypokalemia, hypomagnesemia)
- Pre-existing cardiac disease
- Age > 60 years (who already require the 20 mg maximum dose)
- Concomitant use of other QT-prolonging medications
- Female sex (independent risk factor for TdP)
Follow-up Monitoring
While the 2023 guidelines recommend ECG monitoring when initiating high-risk QT-prolonging drugs 5, real-world data shows poor adherence to monitoring recommendations 8. At minimum, obtain an ECG if the patient develops cardiac symptoms (palpitations, syncope, dizziness) or if additional QT-prolonging drugs are added.
Practical Management Algorithm
- Check current citalopram dose: If > 20 mg/day, reduce to 20 mg/day maximum
- Assess cardiac risk factors: Obtain baseline ECG if any risk factors present
- Verify electrolytes: Correct hypokalemia (goal K+ > 4.0 mEq/L) and hypomagnesemia before starting
- Review medication list: Identify other QT-prolonging drugs using www.crediblemeds.org 5
- Consider alternatives:
Common Pitfalls to Avoid
- Do not assume omeprazole is safe because it doesn't directly prolong QT—the interaction effect is substantial
- Do not overlook age: Patients > 60 years already require 20 mg maximum citalopram dose due to altered pharmacokinetics 1
- Do not ignore CYP2C19 poor metabolizers: These patients also require 20 mg maximum citalopram dose and face even greater interaction risk 1, 9
- Do not combine with other CYP2C19 inhibitors: Esomeprazole has similar interaction magnitude to omeprazole 3
Special Populations
Hepatically impaired patients: Already require 20 mg maximum citalopram dose; adding omeprazole provides no additional dose reduction room—strongly consider alternative SSRI 1.
Elderly patients (> 60 years): The interaction effect is more pronounced in older adults 9, making the 20 mg maximum dose particularly important in this population.
The combination is manageable with appropriate dose limitation and risk assessment, but the 20 mg citalopram maximum is mandatory per FDA labeling 1, 2.